FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2753997908> ?p ?o ?g. }

• W2753997908 abstract "Background The efficacy and safety of certolizumab pegol in the treatment of adult patients with moderate to severe rheumatoid arthritis (RA), when administered either in combination with methotrexate (MTX) or as monotherapy, has been previously shown in several controlled clinical trials. However, a detailed assessment of certolizumab pegol in combination with a wide range of non-biologic disease-modifying drugs (nbDMARDs) used in real-life routine clinical practice is lacking compared to switching to monotherapy after achieving a response when added to nbDMARD(s). Objectives The objective is to compare the effectiveness and tolerability of certolizumab pegol given as add-on to nbDMARDs, including MTX and others, or as monotherapy after achieving a DAS28(ESR) improvement of ≥1.2 In this descriptive interim analysis, preliminary data on the effectiveness of certolizumab pegol given in combination nbDMARDs or monotherapy, are presented. Methods RA patients who had certolizumab pegol added to their existing DMARD regimen due to inadequate response to their nbDMARD(s) were eligible. At 3 or 6 months, those patients who achieved a change in DAS28 of ≥1.2 were randomized to continue combination therapy (Combination group) or withdraw nbDMARD therapy (Monotherapy group) and be followed for 18 months. A sample size of 125 randomized patients per group was calculated to have 100 randomized (50 per group) to find a difference of 15% in response. Results A total of 121 patients were enrolled, of whom 79 were randomized to continue combination therapy (n=35) or withdraw nbDMARDs (n=44). No significant differences were observed between-groups in baseline age, gender (83% vs. 71% female), race (89% vs. 91% Caucasian), rheumatoid factor status (56% vs. 60% positive), or prior biologic experience (17% vs. 11%). At 18 months, upon adjusting for baseline scores, similar improvements were observed between groups in DAS28 ESR (-2.1 vs. -2.0). Furthermore, the odds of achieving DAS28 LDA (OR [95% CI]: 0.96 [0.28–3.31]), ΔDAS28>1.2 (0.97 [0.29–3.26]), or both (1.00 [0.29–1.49]), were not different between the Combination and Monotherapy groups. Similarly, no differences were observed between groups at 12 months of treatment with respect to these outcomes. Conclusions The results of this interim analysis suggest that, among RA patients achieving a therapeutic response when on combination therapy with certolizumab pegol and nbDMARDs, nbDMARDs could be withdrawn without impact on treatment effectiveness over the next year. Additional analyses with the full number of patients will be conducted to confirm this finding. Disclosure of Interest None declared" @default.
• W2753997908 created "2017-09-25" @default.
• W2753997908 creator A5037121360 @default.
• W2753997908 creator A5046734030 @default.
• W2753997908 creator A5054685224 @default.
• W2753997908 creator A5065774384 @default.
• W2753997908 creator A5071924615 @default.
• W2753997908 creator A5075022834 @default.
• W2753997908 creator A5088904022 @default.
• W2753997908 date "2017-06-01" @default.
• W2753997908 modified "2023-10-04" @default.
• W2753997908 title "OP0019 Dmard withdrawal in ra patients achieving therapeutic response with certolizumab pegol combined with dmards: interim results from a canadian observational randomized study" @default.
• W2753997908 doi "https://doi.org/10.1136/annrheumdis-2017-eular.6654" @default.
• W2753997908 hasPublicationYear "2017" @default.
• W2753997908 type Work @default.
• W2753997908 sameAs 2753997908 @default.
• W2753997908 citedByCount "1" @default.
• W2753997908 countsByYear W27539979082020 @default.
• W2753997908 crossrefType "proceedings-article" @default.
• W2753997908 hasAuthorship W2753997908A5037121360 @default.
• W2753997908 hasAuthorship W2753997908A5046734030 @default.
• W2753997908 hasAuthorship W2753997908A5054685224 @default.
• W2753997908 hasAuthorship W2753997908A5065774384 @default.
• W2753997908 hasAuthorship W2753997908A5071924615 @default.
• W2753997908 hasAuthorship W2753997908A5075022834 @default.
• W2753997908 hasAuthorship W2753997908A5088904022 @default.
• W2753997908 hasBestOaLocation W27539979081 @default.
• W2753997908 hasConcept C126322002 @default.
• W2753997908 hasConcept C166957645 @default.
• W2753997908 hasConcept C168563851 @default.
• W2753997908 hasConcept C1862650 @default.
• W2753997908 hasConcept C23131810 @default.
• W2753997908 hasConcept C2776215756 @default.
• W2753997908 hasConcept C2776957806 @default.
• W2753997908 hasConcept C2777575956 @default.
• W2753997908 hasConcept C2780132546 @default.
• W2753997908 hasConcept C61943457 @default.
• W2753997908 hasConcept C71924100 @default.
• W2753997908 hasConcept C95457728 @default.
• W2753997908 hasConceptScore W2753997908C126322002 @default.
• W2753997908 hasConceptScore W2753997908C166957645 @default.
• W2753997908 hasConceptScore W2753997908C168563851 @default.
• W2753997908 hasConceptScore W2753997908C1862650 @default.
• W2753997908 hasConceptScore W2753997908C23131810 @default.
• W2753997908 hasConceptScore W2753997908C2776215756 @default.
• W2753997908 hasConceptScore W2753997908C2776957806 @default.
• W2753997908 hasConceptScore W2753997908C2777575956 @default.
• W2753997908 hasConceptScore W2753997908C2780132546 @default.
• W2753997908 hasConceptScore W2753997908C61943457 @default.
• W2753997908 hasConceptScore W2753997908C71924100 @default.
• W2753997908 hasConceptScore W2753997908C95457728 @default.
• W2753997908 hasLocation W27539979081 @default.
• W2753997908 hasOpenAccess W2753997908 @default.
• W2753997908 hasPrimaryLocation W27539979081 @default.
• W2753997908 hasRelatedWork W1906133657 @default.
• W2753997908 hasRelatedWork W1974821141 @default.
• W2753997908 hasRelatedWork W2078769005 @default.
• W2753997908 hasRelatedWork W2146322086 @default.
• W2753997908 hasRelatedWork W2338322989 @default.
• W2753997908 hasRelatedWork W2340525081 @default.
• W2753997908 hasRelatedWork W2764501944 @default.
• W2753997908 hasRelatedWork W2794762974 @default.
• W2753997908 hasRelatedWork W2895700936 @default.
• W2753997908 hasRelatedWork W4286862964 @default.
• W2753997908 isParatext "false" @default.
• W2753997908 isRetracted "false" @default.
• W2753997908 magId "2753997908" @default.
• W2753997908 workType "article" @default.